Pharmacoeconomic evaluation of carfilzomib <i>versus</i> ixazomib for the treatment of relapsed and refractory multiple myeloma
The study shows that, based on evidence from indirect comparisons, KRd is a cost-effective treatment option for RRMM patients in China.
Authors
- Ruxu You (ORCID: https://orcid.org/0000-0003-3057-4462)
- Jinyu Liu (ORCID: https://orcid.org/0000-0003-0114-0905)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-3618-1491)
- Lin Wang (ORCID: https://orcid.org/0009-0001-0933-0220)
- Fen Chen (ORCID: https://orcid.org/0000-0002-2791-1918)
- Yuanyuan Ma (ORCID: https://orcid.org/0000-0003-1082-7709)
- Xihan Lin
Institutions
- Union Hospital (HK)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Future Science OA
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1080/20565623.2025.2514969
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00